Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00379
|
|||||
| Drug Name |
Melphalan
|
|||||
| Synonyms |
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine; AY3360000; Alanine Nitrogen Mustard; Alkeran; Alkeran (TN); At-290; CB 3025; CB-3025; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Levofalan; Levofolan; Levopholan; MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); Melfalan; Melfalano; Melfalano [INN-Spanish]; Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; Melphalanum; Melphalanum [INN-Latin]; P-Bis(beta-chloroethyl)aminophenylalanine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-L-Sarcolysin; P-L-sarcolysine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; SK-15673; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); TRANSGENIC MODEL EVALUATION (MELPHALAN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Multiple myeloma [ICD11: 2A83] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C13H18Cl2N2O2
|
|||||
| Canonical SMILES |
C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
|
|||||
| InChI |
InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1
|
|||||
| InChIKey |
SGDBTWWWUNNDEQ-LBPRGKRZSA-N
|
|||||
| CAS Number |
CAS 148-82-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 305.2 | Topological Polar Surface Area | 66.6 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10303302
, 10321915
, 11335828
, 11361067
, 11363291
, 11365853
, 11368415
, 11371727
, 11374423
, 11376577
, 11462039
, 11484023
, 11487890
, 11490500
, 11492697
, 11494211
, 14874007
, 14898602
, 17389837
, 24278538
, 26611805
, 26680129
, 26752787
, 46509130
, 47588994
, 47662283
, 47736480
, 47959741
, 48413968
, 48416205
, 48423637
, 48425272
, 49831062
, 49855032
, 49865835
, 50105436
, 50989121
, 53790153
, 56463160
, 57288513
, 57288721
, 57405528
, 611396
, 7847435
, 7979898
, 8149411
, 85789225
, 91010646
, 92307226
, 9332
|
|||||
| ChEBI ID |
ChEBI:28876
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Melphalan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer. 1998;77(2):201-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.